Metformin enhances LDL-cholesterol uptake by suppressing the expression of the pro-protein convertase subtilisin/kexin type 9 (PCSK9) in liver cells

被引：0
|
作者：
Amjad Ali
Hema Unnikannan
Jasmin Shafarin
Khuloud Bajbouj
Jalal Taneera
Jibran Sualeh Muhammad
Haydar Hasan
Albert Salehi
Samir Awadallah
Mawieh Hamad
机构：
[1] University of Sharjah,Sharjah Institute for Medical Research
[2] University of Sharjah,Department of Basic Medical Sciences, College of Medicine
[3] University of Sharjah,Department of Clinical Nutrition and Dietetics, College of Health Sciences
[4] Lund University,Department of Clinical science, UMAS, Clinical Research Center
[5] University of Gothenburg,Department of Neuroscience and Physiology, Metabolic Research Unit
[6] University of Sharjah,Department of Medical Laboratory Sciences, College of Health Sciences
来源：
Endocrine | 2022年 / 76卷
关键词：
Metformin; PCSK9; HNF-1α; SREBP2; LDL-cholesterol; LDLR;
D O I：
暂无
中图分类号：
学科分类号：
摘要：
引用
收藏
页码：543 / 557
页数：14
相关论文
共 50 条
  • [41] Endothelin Receptor Antagonism Improves Lipid Profiles and Lowers PCSK9 (Proprotein Convertase Subtilisin/Kexin Type 9) in Patients With Chronic Kidney Disease
    Farrah, Tariq E.
    Anand, Atul
    Gallacher, Peter J.
    Kimmitt, Robert
    Carter, Edwin
    Dear, James W.
    Mills, Nicholas L.
    Webb, David J.
    Dhaun, Neeraj
    HYPERTENSION, 2019, 74 (02) : 323 - 330
  • [42] Design, synthesis, and biological evaluation of novel tetrahydroprotoberberine derivatives (THPBs) as proprotein convertase subtilisin/kexin type 9 (PCSK9) modulators for the treatment of hyperlipidemia
    Wu, Chenglin
    Xi, Cong
    Tong, Junhua
    Zhao, Jing
    Jiang, Hualiang
    Wang, Jiang
    Wang, Yiping
    Liu, Hong
    ACTA PHARMACEUTICA SINICA B, 2019, 9 (06) : 1216 - 1230
  • [43] Enhanced pro-protein convertase subtilisin/kexin type 9 expression by C-reactive protein through p38MAPK-HNF1α pathway in HepG2 cells
    Cui, Chuan-Jue
    Zhu, Cheng-Gang
    Sun, Jing
    Du, Ying
    Zhang, Yan
    Wu, Na-Qiong
    Guo, Yuan-Lin
    Xu, Rui-Xia
    Gao, Ying
    Li, Jian-Jun
    JOURNAL OF CELLULAR AND MOLECULAR MEDICINE, 2016, 20 (12) : 2374 - 2383
  • [44] Two proprotein convertase subtilisin/kexin type 9 (PCSK9) paralogs from the tropical sea cucumber (Stichopus monotuberculatus): Molecular characterization and inducible expression with immune challenge
    Ren, Chunhua
    Chen, Ting
    Jiang, Xiao
    Sun, Hongyan
    Qian, Jing
    Hu, Chaoqun
    Wang, Yanhong
    FISH & SHELLFISH IMMUNOLOGY, 2016, 56 : 255 - 262
  • [45] Antisense-mediated reduction of proprotein convertase subtilisin/kexin type 9 (PCSK9): a first-in-human randomized, placebo-controlled trial
    van Poelgeest, Eveline P.
    Hodges, Michael R.
    Moerland, Matthijs
    Tessier, Yann
    Levin, Arthur A.
    Persson, Robert
    Lindholm, Marie W.
    Erichsen, Kamille Dumong
    Orum, Henrik
    Cohen, Adam F.
    Burggraaf, Jacobus
    BRITISH JOURNAL OF CLINICAL PHARMACOLOGY, 2015, 80 (06) : 1350 - 1361
  • [46] Circulating Proprotein Convertase Subtilisin/Kexin Type 9 (PCSK9) Concentration and Risk of Cardiovascular Events - Systematic Review and Meta-Analysis of Prospective Studies
    Xiao, Yunjun
    Peng, Chaoqiong
    Huang, Wei
    Zhang, Jinzhou
    Gao, Yang
    Kim, Jean H.
    Yeoh, Eng-kiong
    Su, Xuefen
    CIRCULATION JOURNAL, 2017, 81 (08) : 1150 - 1157
  • [47] Proprotein Convertase Subtilisin/Kexin Type 9 (PCSK9) inhibitors and the risk for neurocognitive adverse events: A systematic review, meta-analysis and meta-regression
    Raccah, Bruria Hirsh
    Yanovsky, Alona
    Treves, Nir
    Rotshild, Victoria
    Renoux, Christel
    Danenberg, Haim
    Eliaz, Ran
    Matok, Ilan
    INTERNATIONAL JOURNAL OF CARDIOLOGY, 2021, 335 : 7 - 14
  • [48] Stroke Prevention With the PCSK9 (Proprotein Convertase Subtilisin-Kexin Type 9) Inhibitor Evolocumab Added to Statin in High-Risk Patients With Stable Atherosclerosis
    Giugliano, Robert P.
    Pedersen, Terje R.
    Saver, Jeffrey L.
    Sever, Peter S.
    Keech, Anthony C.
    Bohula, Erin A.
    Murphy, Sabina A.
    Wasserman, Scott M.
    Honarpour, Narimon
    Wang, Huei
    Lira Pineda, Armando
    Sabatine, Marc S.
    STROKE, 2020, 51 (05) : 1546 - 1554
  • [49] Protein Convertase Subtilisin/Kexin Type 9 Monoclonal Antibodies (PCSK9mab) in Clinical Practice at Secondary Care - Real World Multicentre Experience
    Bashir, Bilal
    Haslam, Shonagh
    Ahmad, Shaheer
    Elnaggar, Mohamed N.
    Allcock, Rebecca
    Ali, Sadaf
    Kyi, Nyan M.
    Salazar, Lorelei
    Gbegbaje, Angela
    Banerjee, Moulinath
    CUREUS JOURNAL OF MEDICAL SCIENCE, 2022, 14 (12)
  • [50] Liraglutide blocks the proliferation, migration and phenotypic switching of Homocysteine (Hcy)-induced vascular smooth muscle cells (VSMCs) by suppressing proprotein convertase subtilisin kexin9 (PCSK9)/low-density lipoprotein receptor (LDLR)
    Ji, Jingquan
    Feng, Ming
    Niu, Xiaohong
    Zhang, Xinyu
    Wang, Yilei
    BIOENGINEERED, 2021, 12 (01) : 8057 - 8066
12345